Summary The association between serum levels of alpha,-antitrypsin (a,AT) at the time of diagnosis and survival was studied in a group of 78 patients with confirmed hepatocellular carcinoma (HCC). All 78 patients were followed until the time of death, which occurred in all instances from HCC, with a median time of 6 months and a range of 1-117 months. Cox's proportional hazards model was utilised in the analysis controlling for sex, age, HBsAg status and logarithmically transformed values of a-fetoprotein (ax-FP). Older patients and patients positive for HBsAg have suggestively higher fatality rates (0.05 <P <0.10) whereas in these data sex and AFP levels were not important prognostic factors. Increased levels of serum a xEAT at the time of diagnosis of HCC were statistically significantly (P <0.05) related with shorter survival, patients with higher serum a,AT by 200 mg 100 ml-' having an expected survival time shorter by about 25%. a,-Antitrypsin (o,AT) is the main protease inhibitor in human serum and its most important biological function is to inactivate a variety of proteolytic enzymes, particularly leukocyte elastase (Harpel, 1983; Cohen, 1986) . Individuals who are homozygous for the Z allele are at an increased risk for hepatocellular carcinoma (HCC) (Eriksson et al., 1986 ), but there is no convincing evidence that individuals who are heterozygous for the Z allelle, and other alleles associated with mjAT deficiency, are over-represented among cases of HCC (Govindarajan et al., 1981; Sparos et al., 1984; Eriksson, 1985; Marwick et al., 1985; Schneider et al., 1986) . Interestingly, several authors have confirmed the observation of Kew et al. (1978) that HCC cases have elevated levels of serum a,AT, an increase which is found across several a,AT phenotypes (Chio & Oon, 1979; Matsuzaki et al., 1981) . In 1984 we reported the results of a relatively large epidemiological study in Greece exploring, among other issues, the association between a,AT levels and HCC, by hepatitis B virus (HBV) serological status (Sparos et al., 1984) . Since then, we have been able to follow, until the time of death, 78 out of the 80 cases with HCC included in that study, and we report here the findings concerning the association between serum levels of a,AT and survival of these patients.
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Patients and methods
In the original study (Trichopoulos et al., 1978) (Trichopoulos et al., 1978 (Trichopoulos et al., , 1980 . Serum levels and phenotypes of a,AT were determined by radial immunodiffusion and electrofocusing in acrylamide gel, respectively (Vesterberg, 1973; Chapuis-Cellier, 1975 (Sparos et al., 1984 (Cox, 1972) , using survival time (there were no censored observations), sex (male = 1, female = 2), age (in decades), HBsAg status (negative = 1, positive = 2), serum a,AT levels (in 100mg 100 ml-') and serum a-FP levels (in ng ml-' after log transformation) as model variables. Cox There is evidence that the fatality rate from HCC is higher among older persons and among patients who are positive for HBsAg, whereas neither sex nor a-FP levels are prognostic indicators in these series. There is a moderately strong positive correlation between serum levels of a,AT and fatality rate from HCC, an increase of 100 mg 100 ml-' corresponding to an increase of death rate of 15% (P-0.05). Proportional hazards model derived fatality rate ratios associated with serum levels of a,AT and other variables. All rates ratios are mutually adjusted. aNot applicable.
identified (Cox, 1978; Morse, 1978; Kuhnl & Spielmann, 1979; Buffone et al., 1983; Dykes et al., 1984) . The association between a,AT and HCC is complex and intriguing, and may reflect both the pathophysiological role of a,AT (Eriksson, 1985; Garver et al., 1986) and its production by the liver (Glasgow et al., 1982) . However, there have been no reports concerning the prognostic significance of a,AT in HCC, although Ishikura et al. (1986) have speculated that the poor prognosis of hepatoid adenocarcinomas of the stomach may be accounted for, in part, by the increased levels of serum axAT frequently noted in these tumours.
The results of the present study indicate that serum levels of a,AT represent an important prognostic factor for survival among patients with HCC. Thus, as a further example, a difference of serum ,1AT of 200 mg 00 ml-' implies a difference of survival time of 25%, and a difference of serum axAT of 400 mg 100 ml-' implies a difference of survival time of more than 40%. It should be noted that the prognostic value of serum axAT is considerably more important than that of serum a-FP; in fact, in the present study, the association of serum a-FP with survival controlling for the serum ajAT, was statistically non-significant and clinically unimportant.
The underlying pathogenesis of the reported association is not clear, but there is some evidence that increased levels of serum axAT may be an indicator of poor prognosis in other malignancies, including breast cancer (Thompson et al., 1983) and cancer of the pancreas (Trichopoulos et al., submitted for publication). The association of serum a1AT with survival may reflect its role as an acute phase protein, since these proteins appear to have prognostic significance in several cancers, possibly through a mediating mechanisms involving suppression of cellular immunity (Baskies et al., 1980; Thompson et al., 1983; Ishikura et al., 1986) . However, a more specific role of axAT in the pathogenesis and natural history of HCC cannot be excluded, given the numerous special links between a,AT and HCC (Sparos et al., 1984; Eriksson et al., 1986) .
